ABL Texcell Diagnostics

ABL Texcell Diagnostics

EEURONEXT:ABLD
2.40
EUR
0.00
(0.00%)
44.70MMarket Cap
Mar 03Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
0.02
0.03
0.04
0.02
- -
- -
- -
0.54
0.35
0.33
0.43
- -
Basic EPS, GAAP
0.03
0.05
0.01
-0.03
- -
0.1
- -
-0.01
0.02
0.07
- -
0.02
0.06
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
0.04
0.01
-0.02
- -
- -
- -
- -
-0.08
0.09
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.35
0.4
0.41
0.42
0.46
0.45
0.44
0.15
0.16
0.42
0.42
0.47
0.47
0.44
Tangible Book Value per Share
0.35
0.39
0.41
0.41
0.45
0.45
0.44
0.15
0.16
0.28
0.26
0.3
0.29
0.24
Basic Weighted Avg Shares
16
16
16
16
16
16
16
16
16
16
16
16
16
16
Sales/Revenue/Turnover
- -
- -
- -
1
1
- -
- -
- -
- -
9
6
5
7
- -
Operating Margin (%)
-365.34
-425.64
-138.76
29.2
28.54
16.49
- -
- -
- -
0.68
-11.71
-9.08
4.18
- -
Depreciation Expense
- -
- -
1
- -
1
-2
- -
- -
- -
1
1
1
1
- -
Net Income, GAAP
- -
1
- -
- -
- -
2
- -
- -
- -
1
- -
- -
1
- -
Effective Tax Rate (%)
264.18
1,512.28
- -
- -
- -
839.61
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
4,439.57
2,147.38
70.35
-90.7
-3.83
472.51
- -
- -
- -
12.64
0.97
5.35
14.2
- -
Working Capital
3
4
2
1
2
7
7
2
3
6
7
7
6
5
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
3
3
3
1
2
Total Equity
6
6
7
7
7
7
7
2
3
7
7
7
8
7
Return on Invested Capital (%)
1.17
12.99
- -
2.39
2.63
-5.53
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
8.76
12.35
- -
-7.45
-0.35
22.31
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
8.8
12.39
3.48
-7.46
-0.36
22.34
-0.88
-1.89
10.36
23.59
0.8
4
13.05
- -

Capital Structure

EUR

•

in mil. unless spec.
Jun'24
Dec'24
Jun'26
ST Debt
1
- -
- -
LT Borrowings
2
3
2
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
16
16
16
Market Capitalization
45
40
45

Working Capital

EUR

•

in mil. unless spec.
Jun'24
Dec'24
Jun'26
Total Current Assets
10
8
9
Cash, Cash Equivalents & STI
2
1
1
Accounts Receivable, Net
3
3
4
Inventories
1
1
2
Total Current Liabilities
5
2
4
Payables & Accruals
- -
- -
- -
ST Debt
1
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.23%
36.31%
1.95%
Free Cash Flow
- -
- -
-211.47%
Net Income, GAAP
-652.45%
103.1%
246%
Sales/Revenue/Turnover
- -
- -
30.39%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
5
2025
- -
- -
7
2026
- -
- -
- -

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.02
2025
- -
- -
0.06
2026
- -
- -
- -

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

CEO
Chalom Sayada
Full Time Employees
21
Sector
Finance
Industry
Financial conglomerates
Address
72c, rue de Thionville Paris IDF France 57140
IPO Date
Mar 25, 1991
Business
ABL Diagnostics Société anonyme (ABLD.PA) is a France-based diagnostic and molecular biology company focused on the development, manufacture, and commercialization of in vitro diagnostic (IVD) assays and related software for infectious disease detection and clinical microbiology. The company provides proprietary molecular biology assays and end-to-end solutions enabling molecular detection by polymerase chain reaction (PCR) and DNA sequencing, complemented by digital and automation software platforms; its product portfolio includes real-time syndromic PCR assays, Nadis patient medical record software used in hospital networks, and clinical sample collection kits such as MediaChek. Headquartered in Woippy, France, ABL Diagnostics operates through direct sales and an international distributor network, targeting academic clinical pathology laboratories, private reference laboratories, and research institutions. The company was founded in 2000 (originating as Etablissements Fauvet Girel) and rebranded to ABL Diagnostics S.A. in 2022, subsequently listing on Euronext Paris. ABL Diagnostics is a subsidiary of Advanced Biological Laboratories (ABL) S.A., a Luxembourg-based diagnostics group, reflecting a broader corporate structure with ongoing strategic alignment within the ABL group. The company maintains operations across France and internationally, delivering products and services to diagnostic laboratories, hospitals, and researchers through a combination of instrument-compatible assays, RUO offerings, and software-enabled data management solutions. Major business lines span molecular detection assays, sequencing-based workflows, laboratory automation integration, digital health software, and related lab infrastructure products, with a focus on HIV, hepatitis, tuberculosis, and other infectious disease areas. Ongoing strategic activities include capital market movements related to shareholding changes by the principal shareholder, ABL S.A., and continued expansion of product lines, partnerships, and geographic coverage to support diagnostic workflows in both routine clinical laboratories and research settings.